NCT02753309View on ClinicalTrials.gov

A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 1, 2019

Study Completion Date

March 2, 2021

Conditions
Bladder Cancer
Interventions
DRUG

Sirolimus

Trial Locations (1)

78229

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02753309 - A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter